Vabysmo (faricimab-svoa) targets and inhibits two disease pathways that drive wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Vabysmo is the only injectable eye medicine approved simultaneously in the US for wet...

(RTTNews) - As we head into the fourth quarter of 2021, here is a recap of what happened on the regulatory front this month that caught our attention. Samsung Bioepis' Byooviz became the first biosimilar for Lucentis to treat macular...

Cancer is the second leading cause of death worldwide, with nearly 10 million deaths annually.1,2 In the U.S., approximately 1.9 million new cancer cases are expected to be diagnosed in 2021.1 Based on cancer biomarkers, the...